Valneva (NASDAQ:VALN) Shares Gap Down – Here’s Why

Valneva SE Sponsored ADR (NASDAQ:VALN)’s share price gapped down before the market opened on Thursday. The stock had previously closed at $5.87, but opened at $5.61. Valneva shares last traded at $5.6550, with a volume of 6,142 shares trading hands.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a research note on Monday, September 14th. TD Cowen initiated coverage on Valneva in a research report on Tuesday, August 11th. They set a “buy” rating and a $12.00 target price for the company. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $9.30.

Valneva Price Performance

The stock has a market capitalization of $548.46 million, a P/E ratio of -2.74 and a beta of 1.53. The company’s 50 day simple moving average is $6.30 and its two-hundred day simple moving average is $5.84. The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69.

Valneva (NASDAQ:VALN) last announced its earnings results on Friday, August 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The business had revenue of $39.37 million during the quarter, compared to analyst estimates of $44.17 million. Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. As a group, equities analysts expect that Valneva SE Sponsored ADR will post -1.27 EPS for the current fiscal year.

Valneva Company Profile

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.